3rd Quarter - Report
CAPITOL HILL CONSULTING GROUP for NOVARTIS CORPORATION
Client
Income
$30,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation act. H.R. 5182, the Promoting Life-Saving New Therapies for Neonates Act of 2016
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID JORY | — |
| BRIAN SUTTER | Staff Dir., W&M Health Subcommittee, Chairman Dave Camp April, 2013 - Dec. 2014; Professional Staff, W&M Health Subcommittee, Chairman Dave Camp, Jan. 2011 - April 2013;Leg Dir., Rep. Dave Camp, May '08 - Jan.,'11 Leg Asst.Rep Camp, Feb '03-May'08; |
Taxation/Internal Revenue Code TAX
General Corporate Tax Reform; Orphan Drug Credit; Research and Experimentation Tax Credit Extension; International corporate taxation; Inversion regulations and legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID JORY | — |
| BRIAN SUTTER New | Staff Dir., W&M Health Subcommittee, Chairman Dave Camp April, 2013 - Dec. 2014; Professional Staff, W&M Health Subcommittee, Chairman Dave Camp, Jan. 2011 - April 2013;Leg Dir., Rep. Dave Camp, May '08 - Jan.,'11 Leg Asst.Rep Camp, Feb '03-May'08; |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.